Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Myogenin, AP2β, NOS-1, and HMGA2 are surrogate markers of fusion status in rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the children's oncology group.

Rudzinski ER, Anderson JR, Lyden ER, Bridge JA, Barr FG, Gastier-Foster JM, Bachmeyer K, Skapek SX, Hawkins DS, Teot LA, Parham DM.

Am J Surg Pathol. 2014 May;38(5):654-9. doi: 10.1097/PAS.0000000000000195.

2.

Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Rudzinski ER, Teot LA, Anderson JR, Moore J, Bridge JA, Barr FG, Gastier-Foster JM, Skapek SX, Hawkins DS, Parham DM.

Am J Clin Pathol. 2013 Jul;140(1):82-90. doi: 10.1309/AJCPA1WN7ARPCMKQ.

3.

Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.

Heerema-McKenney A, Wijnaendts LC, Pulliam JF, Lopez-Terrada D, McKenney JK, Zhu S, Montgomery K, Mitchell J, Marinelli RJ, Hart AA, van de Rijn M, Linn SC.

Am J Surg Pathol. 2008 Oct;32(10):1513-22. doi: 10.1097/PAS.0b013e31817a909a.

PMID:
18708938
4.

Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.

Laé M, Ahn EH, Mercado GE, Chuai S, Edgar M, Pawel BR, Olshen A, Barr FG, Ladanyi M.

J Pathol. 2007 Jun;212(2):143-51.

PMID:
17471488
5.

Classification of rhabdomyosarcoma and its molecular basis.

Parham DM, Barr FG.

Adv Anat Pathol. 2013 Nov;20(6):387-97. doi: 10.1097/PAP.0b013e3182a92d0d. Review.

PMID:
24113309
6.

Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.

Williamson D, Missiaglia E, de Reyniès A, Pierron G, Thuille B, Palenzuela G, Thway K, Orbach D, Laé M, Fréneaux P, Pritchard-Jones K, Oberlin O, Shipley J, Delattre O.

J Clin Oncol. 2010 May 1;28(13):2151-8. doi: 10.1200/JCO.2009.26.3814. Epub 2010 Mar 29.

PMID:
20351326
7.

Rhabdomyosarcoma: value of myogenin expression analysis and molecular testing in diagnosing the alveolar subtype: an analysis of 109 paraffin-embedded specimens.

Hostein I, Andraud-Fregeville M, Guillou L, Terrier-Lacombe MJ, Deminière C, Ranchère D, Lussan C, Longavenne E, Bui NB, Delattre O, Coindre JM.

Cancer. 2004 Dec 15;101(12):2817-24.

8.

ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status.

Corao DA, Biegel JA, Coffin CM, Barr FG, Wainwright LM, Ernst LM, Choi JK, Zhang PJ, Pawel BR.

Pediatr Dev Pathol. 2009 Jul-Aug;12(4):275-83. doi: 10.2350/08-03-0434.1.

PMID:
18788887
9.

PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.

Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, Bridge JA, Crist WM, Triche TJ, Barr FG.

J Clin Oncol. 2002 Jun 1;20(11):2672-9.

PMID:
12039929
10.

PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.

Skapek SX, Anderson J, Barr FG, Bridge JA, Gastier-Foster JM, Parham DM, Rudzinski ER, Triche T, Hawkins DS.

Pediatr Blood Cancer. 2013 Sep;60(9):1411-7. doi: 10.1002/pbc.24532. Epub 2013 Mar 22.

11.

Results of a prospective minimal disseminated disease study in human rhabdomyosarcoma using three different molecular markers.

Sartori F, Alaggio R, Zanazzo G, Garaventa A, Di Cataldo A, Carli M, Rosolen A; AIEOP Comitato Strategico de Studio-Sarcomi..

Cancer. 2006 Apr 15;106(8):1766-75.

12.

Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: a report from the Children's Oncology Group.

Duan F, Smith LM, Gustafson DM, Zhang C, Dunlevy MJ, Gastier-Foster JM, Barr FG.

Genes Chromosomes Cancer. 2012 Jul;51(7):662-74. doi: 10.1002/gcc.21953. Epub 2012 Mar 23.

13.

Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group.

Arnold MA, Anderson JR, Gastier-Foster JM, Barr FG, Skapek SX, Hawkins DS, Raney RB Jr, Parham DM, Teot LA, Rudzinski ER, Walterhouse DO.

Pediatr Blood Cancer. 2016 Apr;63(4):634-9. doi: 10.1002/pbc.25862. Epub 2016 Jan 12.

14.

Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group.

Davicioni E, Anderson MJ, Finckenstein FG, Lynch JC, Qualman SJ, Shimada H, Schofield DE, Buckley JD, Meyer WH, Sorensen PH, Triche TJ.

Am J Pathol. 2009 Feb;174(2):550-64. doi: 10.2353/ajpath.2009.080631. Epub 2009 Jan 15.

15.

Detection of FOXO1 (FKHR) gene break-apart by fluorescence in situ hybridization in formalin-fixed, paraffin-embedded alveolar rhabdomyosarcomas and its clinicopathologic correlation.

Mehra S, de la Roza G, Tull J, Shrimpton A, Valente A, Zhang S.

Diagn Mol Pathol. 2008 Mar;17(1):14-20. doi: 10.1097/PDM.0b013e3181255e62.

PMID:
18303411
16.

Correlation between histology and PAX/FKHR fusion status in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group.

Parham DM, Qualman SJ, Teot L, Barr FG, Morotti R, Sorensen PH, Triche TJ, Meyer WH; Soft Tissue Sarcoma Committee of the Children's Oncology Group..

Am J Surg Pathol. 2007 Jun;31(6):895-901.

PMID:
17527077
17.

[Expression of fusion gene PAX3/PAX7-FKHR and chromosomal aberration in rhabdomyosarcoma].

Gao H, Ou YL, Zhang KR, Zhang ZB, Wang WL.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2007 Feb;24(1):42-7. Chinese.

PMID:
17285543
18.

The comparative utility of fluorescence in situ hybridization and reverse transcription-polymerase chain reaction in the diagnosis of alveolar rhabdomyosarcoma.

Thway K, Wang J, Wren D, Dainton M, Gonzalez D, Swansbury J, Fisher C.

Virchows Arch. 2015 Aug;467(2):217-24. doi: 10.1007/s00428-015-1777-9. Epub 2015 Apr 26.

PMID:
25912319
20.

Rhabdomyosarcoma: molecular analysis of Igf2, MyoD1 and Myogenin expression.

Krskova L, Augustinakova A, Drahokoupilova E, Sumerauer D, Mudry P, Kodet R.

Neoplasma. 2011;58(5):415-23.

PMID:
21744995

Supplemental Content

Support Center